Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORT247 SAD study in healthy volunteers
NCT06769620Phase 1Completed
- Sponsor
- Orthogonal Neuroscience
- Start
- Jun 2022
- Primary completion
- Oct 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing ORT247 with Placebo (2 arms). Primary endpoint: Number of participants with treatment-emergent adverse events at Day 85. Started Jun 2022; status: completed.
02
Drugs
ORT-247
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06769620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06769620.